Guerard Frederic 4

What Happened Guerard Frederic, an outside director of LENZ Therapeutics, was granted a derivative award on June 15, 2026 covering 22,100 shares. The filing records an acquisition price of $0 and total value $0 for this award; the form classifies the transaction as an award/grant (transaction code A) rather than a cash purchase or sale. A footnote in the filing states the award is subject to vesting conditions tied to continued service.

Key Details

• Transaction date: 2026-06-15; Transaction type: Grant/Award (derivative)
• Shares/units granted: 22,100; Acquisition price shown: $0; Reported total value: $0
• Vesting: 100% of the shares subject to the option vest on the earlier of June 15, 2027 or the date of the next annual meeting of stockholders, contingent on the reporting person remaining an Outside Director
• Shares owned after transaction: Not specified in the provided filing summary
• Filing timeliness: Report filed on 2026-06-15 for a 2026-06-15 transaction (appears timely)

Context This is an equity compensation award for an outside director — specifically a derivative/option-style grant that vests upon continued service. It does not represent an immediate market purchase or sale of stock and therefore is not a direct trading signal; instead it reflects customary board compensation tied to future vesting conditions.